InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,193.11
(
-1.09%
)
Post# of 255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 137
Posts 22855
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: None

Friday, 10/30/2020 9:38:08 PM

Friday, October 30, 2020 9:38:08 PM

Post# of 255
Axovant needs a PR to explain that Oxford BioMedica MUST dedicate capacity to produce adenovirus vectors for the Astrazeneca AZD1222 vaccine for Covid 19 and the Novartis Kymriah® cancer gene therapy.

This is a priority over the Parkinson's gene therapy for the Axovant trial.
The Axovant trial is very promising and is just delayed due to the covid 19 pandemic.

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-signs-supply-agreement-astrazeneca-expand-manufacturing

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-extends-commercial-supply-agreement-five-years-manufacture

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-notes-axovant-s-positive-six-month-follow-second-cohort

Good luck and GOD bless,
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up